2019 Ryan White HIV/AIDS Program CLINICAL CONFERENCE

Mortality after MI by type

Feinstein,2019,BMC

Slide22of 43FromHMCrane, MD inNewOrleans, LA, December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA.

Roadmap ▪ Why do we care? ▫ HIV infected vs. uninfected, incidence ▪ MI types in HIV ▫ Universal MI definition ▫ CNICS MI adjudication ▫ Type 1 vs. Type 2 MIs ▪ Why increased risk ▪ Other CVD ▪ What do we do? ▫ Risk scores ▪ Summary

Slide23of 43FromHMCrane, MD inNewOrleans, LA, December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA.

Why?

Figure adapted from: Hsue et al. JID . 2012

Currier. TopHIVMed 2009 Post Ann Intern Med . 2014 Slide courtesy of M.Feinstein

Slide24of 43FromHMCrane, MD inNewOrleans, LA, December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA.